Stoke Therapeutics

53 articles with Stoke Therapeutics

• Stoke Therapeutics Announces Presentations Related to the Company’s Work in Dravet Syndrome at the American Epilepsy Society 2020 Virtual Annual Meeting

  11/25/2020

  Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that four abstracts related to the Company’s work in Dravet syndrome have been selected for presentation at the upcoming American Epilepsy Society (AES) 2020 Virtual Annual Meeting

• Stoke Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  11/24/2020

  Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the closing of its underwritten public offering of 2,875,000 shares of its common stock, including 375,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares,

• Stoke Therapeutics Announces Pricing of $97.5 Million Public Offering

  11/20/2020

  Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $39.00 per share.

• Stoke Therapeutics Announces Proposed Public Offering

  11/18/2020

  Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to 2,500,000 shares of its common stock

• Stoke Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

  11/9/2020

  Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020, at 3:20 p.m. ET. A live audio webcast of the presentation will b

• Stoke Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare Conference

  11/2/2020

  Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will participate in a fireside chat at the 29th Annual Credit Suisse Vi

• Stoke Therapeutics Announces Plans to Move Forward With Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1/2a MONARCH Study for Dravet Syndrome

  10/7/2020

  New Preclinical Repeat-Dose Data Support Company Plans to Evaluate Multiple Ascending Dose Levels in MONARCH, Subject to FDA Review

• Stoke Therapeutics to Present at Cantor Virtual Global Healthcare Conference

  9/9/2020

  Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020, at 9:20 a.m. ET. A live webcast of the presentation will be available on t

• Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine that Demonstrate Significant Improvements in Survival and Reductions in Seizure Frequency in a Dravet Syndrome Mouse Model

  8/26/2020

  Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine that Demonstrate Significant Improvements in Survival and Reductions in Seizure Frequency in a Dravet Syndrome Mouse Model STK-001 has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome A Phase 1/2a study of STK-001 in children and adolescents ages 2 to 18 years old is now underway

• Stoke Therapeutics Announces Appointment of Garry E. Menzel, Ph.D., to its Board of Directors

  8/17/2020

  Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the appointment of Garry E. Menzel, Ph.D., to both its Board of Directors and Compensation Committee. “Garry brings more than 25 years of exe

• Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

  8/10/2020

  – First patient dosed with STK-001 in Part A of Phase 1/2a MONARCH clinical trial for Dravet syndrome – – Company on track to identify an additional pre-clinical candidate derived from its TANGO platform for the treatment of an additional genetic disease in 2H 2020 – – As of June 30, 2020, company has $202.1 million in cash, cash equivalents and restricted cash, anticipated to fund operations into 2023 –

• Stoke Therapeutics to Present at Upcoming Investor Conferences in August

  8/4/2020

  Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that members of management will present at three upcoming investor conferences in August: 2020 Wedbush PacGrow Healthcare Virtual Conference Date: Tuesday, August 11, 2020 Time: 11:30 a.m. ET BTIG Virtual Bio

• Stoke Therapeutics Announces Publication of Data in the Journal Nature Communications That Support the Company’s Proprietary Approach to Addressing Severe Genetic Diseases by Precisely Upregulating Protein Expression

  7/9/2020

  Stoke’s TANGO antisense oligonucleotides showed dose-dependent reductions in non-productive mRNA and increases in both productive mRNA and protein levels from genes of diverse size, type and function

• Stoke Therapeutics Appoints Julie Anne Smith to its Board of Directors

  6/4/2020

  Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the appointment of Julie Anne Smith to its Board of Directors. Ms. Smith has also been appointed to the Compensation Committee of the Boa

• Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

  5/15/2020

  Company on track to begin enrollment and dosing of STK-001 in Part A of Phase 1/2a “Monarch” clinical trial in children and adolescents with Dravet syndrome in 2H 2020 – – Research activities ongoing to identify an additional preclinical candidate derived from the company’s TANGO technology platform for the treatment of an additional genetic disease in 2H 2020– – As of March 31, 2020, company has $211.5 million in cash, cash equivalents and res

• Stoke Therapeutics Presents Preclinical Data That Demonstrate In-Vitro and In-Vivo Target Engagement and Protein Upregulation in OPA1 Protein Deficiency, the Primary Cause of the Most Common Inherited Optic Nerve Disorder

  5/12/2020

  Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced new preclinical data demonstrating in-vitro and in-vivo target engagement and protein upregulation in OPA1 protein-deficient cells.

• Stoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business Updates

  3/23/2020

  Stoke Therapeutics today reported financial results for the full year ended December 31, 2019, and provided business updates.

• Stoke Therapeutics to Present at 40th Annual Cowen Health Care Conference

  2/24/2020

  Feb. 24, 2020 13:00 UTC Stoke Therapeutics to Present at 40 th Annual Cowen Health Care Conference BEDFORD, Mass.--( BUSINESS WIRE )-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the 40 th Annual Cowen Health Care Conference on Monday, March 2, 2020 at 3:3

• Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference

  1/7/2020

  Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the 38th Annual J.P. Morgan Healthcare Conference

• Stoke Therapeutics Added to NASDAQ Biotechnology Index

  12/23/2019

  Stoke Therapeutics, Inc. (Nasdaq:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI).